CliffBio
small molecule

SODIUM PHENYLACETATE AND SODIUM BENZOATE

SODIUM BENZOATE; SODIUM PHENYLACETATE

Loss of exclusivity—loss of exclusivity
CompanyMaia →See this company's full patent-cliff portfolio

Drug detail

Brand nameSODIUM PHENYLACETATE AND SODIUM BENZOATE
Active ingredientSODIUM BENZOATE; SODIUM PHENYLACETATE
Strength10%;10% (2GM/20ML;2GM/20ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusRX

More from Maia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SODIUM PHENYLACETATE AND SODIUM BENZOATE patent cliff — loss of exclusivity — | CliffBio